OX40 Atopic Dermatitis: A Drug Class Ended in 175 Days and 8,185 Patients
Witfire Elite · Clinical Catalysts · Registry Analysis OX40 atopic dermatitis development is over. Two companies, two mechanisms, 175 days. The press releases said…
Witfire Coverage
Category: Pharma Market Case Studies
Teva Q2 2026 Results: What the Numbers Actually Say
Teva's Q2 2026 revenue fell 1%, operating income fell $686M and the shares rose 8.6%. All three follow from one subtraction the release never performs: US generics lost $301M in the quarter, and three branded products added $306M.
J&J Talc Settlement: $5.5 Billion, 76,000 Claims and the 95% Condition
Witfire Elite · Litigation Risk Brief · Product Liability Johnson & Johnson won a causation ruling. One week later it settled anyway. Understanding why…
Novo Nordisk Eli Lilly Lawsuit: What the Case Turns On
Witfire Elite · Litigation Risk Brief · GLP-1 Series No. 04 Novo Nordisk vs Eli Lilly: The Obesity Ad War Neither Side Can Win…
Sun Pharma Organon Deal: Why 2027 Decides Everything
Witfire Elite · M&A Risk Brief · Deal No. 2026-07 Sun Pharma’s $11.75B Organon Deal: Platform Acquisition or Debt-Heavy Scale Bet? Shareholders cleared the…
Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha
Witfire Elite · Cardiometabolic Risk Brief · Pricing & Access Oral PCSK9 Inhibitor Approved: LIPFENDRA Lists at $315. Repatha Already Sells for $239. The…
The Stabilizer Ceiling: What 3 Amyloidosis Trials Reveal
Witfire Elite · Trial Design & Strategy · Framework HELIOS-B vs CARDIO-TTRansform: What the Eplontersen Miss Reveals HELIOS-B cleared its endpoint. CARDIO-TTRansform missed. CARES…
Eplontersen CARDIO-TTRansform Miss: ATTR-CM Analysis
Witfire Elite · Trial Design & Strategy · Framework HELIOS-B vs CARDIO-TTRansform: What the Eplontersen Miss Reveals HELIOS-B cleared its endpoint. CARDIO-TTRansform missed. CARES…
Achieve Cytisinicline CRL: Rejection That Did Not Break the Company
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-07 Achieve’s Cytisinicline CRL: The Rejection That Was Priced Before It Arrived Same…
Unicycive OLC CRL: The CMC Failure Behind a Biotech Selloff
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-06 The CMC Execution Crisis: Why Unicycive’s Second CRL Is a Warning Shot…